Skip to main content
. 2018 Nov 22;2018:5642148. doi: 10.1155/2018/5642148

Figure 2.

Figure 2

Changes in gene expression induced by sulforaphane in early passage, nonsenescent MRC-5 cells in vitro. Key: + 1 μM SFN (○▬○) and control, + 0.002% DMSO (●····●). (a) NQO1 (P = 2 × 10−4, P′ = 0.003, and P ″ = 0.006), (b) GCLM (P = 0.003, P′ = 0.020, and P ″ = 0.005), (c) GSR (P = 0.017, P′ = 0.006, and P ″ = 0.019), (d) HMOX1 (P = 0.006, P′ = 0.011, and P ″ = 0.014), (e) TXN (P = 0.005, P′ = 0.008, and P ″ = 0.034), (f) TXNRD1 (P = 8 × 10−4, P′ = 0.004, and P ″ = 0.004), (g) G6PD (P = 0.002, P′ = 0.013), (h) TXT (P = 0.003, P′ = 0.001, and P ″ = 0.018), (i) TALDO (P = 0.004, P′ = 0.004, and P ″ = 0.034), (j) SQSTM1 (P = 7 × 10−4, P′ = 0.002, and P ″ = 0.004), (k) PSMA1 (P = 0.015), (l) PSMB5, (m) NFE2L2 (P = 0.008), (n) KEAP1 (P = 0.045), (o) MAFG (P = 3 × 10−4, P′ = 0.011, and P ″ = 0.031), (p) FYN (P = 0.001), (q) GLB1 (P = 0.017), (r) ELN (P = 0.012), (s) CTSO (P = 0.024), and (t) SREBF1 (P = 0.014, P′ = 0.041). Data are mean ± SD, N = 3. Significance: P, P′, and P ″, significance values for time, SFN treatment, and time × SFN treatment effects, respectively (n = 48); ANOVA repeated measures.